Spyre Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Spyre Therapeutics'in kazançlarının yıllık 17.2% oranında azalacağı tahmin edilmektedir. EPS'nin azalması yıllık 7.6% oranında azalması beklenmektedir.

Anahtar bilgiler

-17.2%

Kazanç büyüme oranı

-7.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.4%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	04 Mar 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Mar 04

Spyre Therapeutics: Different Name, Same Tune

Dec 12

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Oct 01

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:SYRE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	N/A	-300	-238	-241	5
12/31/2026	N/A	-256	-218	-227	8
12/31/2025	N/A	-218	-189	-179	8
12/31/2024	N/A	-150	-157	-157	N/A
9/30/2024	N/A	-215	-151	-151	N/A
6/30/2024	N/A	-186	-141	-156	N/A
3/31/2024	1	-364	-96	-111	N/A
12/31/2023	1	-95	-85	-100	N/A
9/30/2023	1	-294	-72	-87	N/A
6/30/2023	1	-273	-67	-67	N/A
3/31/2023	1	-78	-72	-72	N/A
12/31/2022	2	-84	-80	-80	N/A
9/30/2022	6	-85	-81	-81	N/A
6/30/2022	7	-88	-83	-83	N/A
3/31/2022	20	-72	-61	-60	N/A
12/31/2021	19	-66	-54	-54	N/A
9/30/2021	15	-68	-53	-52	N/A
6/30/2021	14	-66	-54	-52	N/A
3/31/2021	N/A	-80	-77	-74	N/A
12/31/2020	N/A	-81	-80	-76	N/A
9/30/2020	N/A	-80	-79	-75	N/A
6/30/2020	N/A	-83	-79	-75	N/A
3/31/2020	N/A	-80	-74	-72	N/A
12/31/2019	N/A	-78	-67	-66	N/A
9/30/2019	N/A	-72	-57	-57	N/A
6/30/2019	N/A	-62	-48	-48	N/A
3/31/2019	2	-53	-41	-41	N/A
12/31/2018	4	-44	-33	-32	N/A
9/30/2018	5	-36	N/A	-31	N/A
6/30/2018	7	-32	N/A	-30	N/A
3/31/2018	6	-29	N/A	-27	N/A
12/31/2017	5	-27	N/A	-25	N/A
9/30/2017	5	-26	N/A	-23	N/A
6/30/2017	5	-25	N/A	-22	N/A
3/31/2017	5	-23	N/A	-20	N/A
12/31/2016	5	-22	N/A	-19	N/A
9/30/2016	5	-20	N/A	-15	N/A
6/30/2016	5	-17	N/A	-13	N/A
3/31/2016	7	-13	N/A	-12	N/A
12/31/2015	6	-12	N/A	-11	N/A
9/30/2015	5	-11	N/A	-13	N/A
6/30/2015	3	-11	N/A	-11	N/A
3/31/2015	N/A	-12	N/A	-8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SYRE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: SYRE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: SYRE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: SYRE şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: SYRE gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SYRE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/03/17 03:49
Gün Sonu Hisse Fiyatı	2025/03/14 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Spyre Therapeutics, Inc. 16 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Colleen Kusy	Baird
Mayur Somaiya	BMO Capital Markets Equity Research
Julian Harrison	BTIG

Spyre Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

No longer forecast to breakeven

Price target increased to US$2.70

Recent updates

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Spyre Therapeutics: Different Name, Same Tune

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies

Spyre Therapeutics, Inc. has completed a Follow-on Equity Offering.

Spyre Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Spyre Therapeutics, Inc. Announces Positive Interim Phase 1 Data from its First-In-Human Trial of SPY001

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics, Inc. Announces First Participants Dose in Phase 1 Trial of SPY001

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding from a group of investors

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors

Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors

Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Aeglea Biotherapeutics, Inc. Regains Compliance with Nasdaq Listing Rule

Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Immedica Pharma signed an agreement to acquire global rights to pegzilarginase from Aeglea BioTherapeutics, Inc from Aeglea BioTherapeutics, Inc. (NasdaqCM:AGLE) for $115 million.

Aeglea Biotherapeutics Receives Approval from Nasdaq of the Transfer of the Listing of Its Common Stock from Nasdaq Global Market to the Nasdaq Capital Market

High number of new directors

Aeglea BioTherapeutics, Inc. announced that it expects to receive $210.000248 million in funding from a group of investors

Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE) acquired Spyre Therapeutics, Inc. for $1.42 million.

New major risk - Share price stability

Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer

Aeglea BioTherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

No longer forecast to breakeven

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Aeglea BioTherapeutics Receives Written Notice from The Nasdaq Stock Market, LLC Regarding Minimum Bid Price Requirement for Continued Listing

Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer

Aeglea Biotherapeutics, Inc. Announces Chief Executive Officer Changes

Aeglea BioTherapeutics, Inc. Appoints Linda Neuman as Chief Medical Officer

Price target increased to US$2.70

Consensus forecasts updated

Price target increased to US$2.70

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea BioTherapeutics, Inc. Provides Clinical Progress and Regulatory Update for Homocystinuria Program

Insider recently bought US$50k worth of stock

Aeglea Biotherapeutics Announces Leadership Transition

Aeglea BioTherapeutics, Inc. Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Consensus forecasts updated

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics Receives Non-Compliance Notice from Nasdaq

Aeglea BioTherapeutics Announces Resignation of Sandesh Mahatme as Director

Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped from Russell 2000 Dynamic Index

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Biotherapeutics, Inc. Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Consensus revenue estimates increase by 36%

Price target decreased to US$9.86

Price target decreased to US$11.00

Aeglea BioTherapeutics, Inc. Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc. Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

Consensus revenue estimates increase by 76%

President recently bought US$281k worth of stock

Consensus forecasts updated

Price target decreased to US$11.00

Aeglea Biotherapeutics, Inc. Announces Resignation of Sara Brownstein as Class I Director of the Board

Independent Director recently bought US$550k worth of stock

Aeglea BioTherapeutics, Inc. Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency

Price target decreased to US$12.43

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Chief Financial Officer recently bought US$263k worth of stock